Le Lézard
Classified in: Health, Science and technology
Subject: Stock Sale/Buyback

ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)


ImmunoGen, Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today announced that on April 29, 2022, the compensation committee of the Company's Board of Directors approved grants of non-qualified stock option awards to purchase an aggregate of 729,530 shares of its common stock to sixteen new employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan, as amended (the "Inducement Plan"). The stock options were granted as an inducement material to the new employees' becoming employees of ImmunoGen in accordance with Nasdaq Listing Rule 5635(c)(4).

The Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously employees of ImmunoGen (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with ImmunoGen, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules.

The options have an exercise price of $4.83 per share, which is equal to the closing price of ImmunoGen's common stock on the Nasdaq Global Select Market on April 29, 2022. Each option will vest over a four-year period, with 25% of the shares vesting on the one-year anniversary of the date of grant, and thereafter an additional 6.25% of the shares vesting on each succeeding quarterly anniversary of the date of grant, subject to such employee's continued employment with ImmunoGen on such vesting dates. Each option is subject to the terms and conditions of the Inducement Plan and the terms and conditions of a stock option agreement covering the grant.

ABOUT IMMUNOGEN

ImmunoGen is developing the next generation of antibody-drug conjugates to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOWtm.

Learn more about who we are, what we do, and how we do it at www.immunogen.com.


These press releases may also interest you

at 23:35
Accenture has agreed to acquire Romp, a brand and experience agency in Indonesia renowned for its creative talent and innovative services across branding, creative and performance marketing. The move will strengthen Accenture Song's (formerly...

at 23:35
The 2022 Taihu Bay Future Healthcare Conference held Thursday in Wuxi City in east China's Jiangsu Province witnessed the launch of Wuxi Intellectual Property Protection Center with 52 biomedical projects contracted, involving a total of more than 30...

at 21:30
The demand for mobile point-of-sale (mPOS)...

at 21:05
BioDuro-Sundia, an industry-leading drug discovery, development and commercial service CRDMO backed by Advent International, and X-Chem, a DEL technology pioneer in small molecule drug discovery, jointly announced the launch of DNA Encoded Compound...

at 21:00
LG Electronics USA announced today the 2022 lineup of TONE Free® true wireless earbuds. The new models provide the ultimate sound experience with advanced audio technologies, a better-fitting design, and a host of useful, new features. The new TONE...

at 20:30
On August 1, 2022, U.S. time, ImmVira's brand new oncolytic herpes simplex virus ("oHSV") product MVR-C5252 targeting Malignant Glioma has obtained Orphan Drug Designation ("ODD") from U.S. Food and Drug Administration ("FDA"). Malignant glioma has...



News published on 2 may 2022 at 16:35 and distributed by: